Monday 2 November 2026 Export TWST’s income statement to Excel — free account

Twist Bioscience Corporation

Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.

Revenue: +23.2%
EPS: −264.7%
Free cash flow: −7.23%
Total debt: 0.00%

Quarter to June 2026, against a year earlier

129.86 22.92 −15.00%

Follow TWST

Alert me

Market cap: $10.1B
P/E: 0.0×
Fwd P/E: −91.4×
Dividend yield: —
F-score: 4/9
Altman Z: 3.44
Beneish M: −2.30
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Filings

Twist Bioscience Corporation (TWST) revenue by segment, product and region

	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023	Q2 FY2023	Q1 FY2023
NGS applications	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Synthetic genes	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
DNA synthesis and protein solutions	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Oligo pools	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
DNA libraries	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Twist Bioscience Corporation (TWST) revenue by segment, product and region

Stockrow Weekly